Vernal Keratoconjunctivitis Epidemiology Forecast till 2030

August 28 08:51 2020
Vernal Keratoconjunctivitis Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Vernal Keratoconjunctivitis – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Vernal Keratoconjunctivitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Vernal Keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae.

 

Vernal Keratoconjunctivitis Epidemiology Segmentation in Total Major Market from 2017 to 2030

  • Total Prevalent Population of Vernal Keratoconjunctivitis
  • Total Diagnosed Prevalent Cases of VKC
  • Gender-specific Diagnosed Prevalent Cases of VKC
  • Type-specific Diagnosed Prevalent Cases of VKC
  • Severity-specific Diagnosed Prevalent Cases of VKC
  • Age-specific Diagnosed Prevalent Cases of VKC

Vernal Keratoconjunctivitis Epidemiology Insights

  • Total prevalent population of Vernal Keratoconjunctivitis in the total market (7MM, China, Egypt, Saudi Arabia and Russia) in 2017  was 4,752,356
  • The prevalence of VKC in the United States in 2017 was  65,309
  • Among the EU-5 countries, the prevalent population of VKC in 2017 in Italy was 172,591 whereas in Spain, it was 15,645. 
  • The diagnosed prevalence was higher for males as compared to females in all the total major markets countries
  • China contributes the largest share in 2017 was 2,248,706

 

Scope of the Report

  • The Vernal Keratoconjunctivitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Vernal Keratoconjunctivitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Vernal Keratoconjunctivitis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Vernal Keratoconjunctivitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Vernal Keratoconjunctivitis
  • The report provides the segmentation of the Vernal Keratoconjunctivitis epidemiology

 

Request for sample pages
Table of contents

1. Key Insights

2. Executive Summary of Vernal keratoconjunctivitis (VKC)

3. Vernal keratoconjunctivitis (VKC): Epidemiology Overview at a Glance

3.1. Total Epidemiological Share (%) Distribution of VKC in 2017

3.2. Total Epidemiological Share (%) Distribution of VKC in 2030

4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC)

4.1. Introduction

4.2. Signs and Symptoms of VKC

4.2.1. Signs

4.3. Causes

4.4. Risk Factors

4.5. Grades of VKC

4.6. Pathophysiology

4.6.1. Mediators in VKC

4.6.2. Cells in VKC

4.7. Histopathology

4.8. Diagnosis of VKC

5. Case Reports

5.1. Vernal Keratoconjunctivitis: A Teaching Case Report

5.2. Ocular surface disease: A case of vernal keratoconjunctivitis

5.3. Topical and Oral Cyclosporine for a Case of Severe Limbal Vernal Keratoconjunctivitis with Complete Corneal Involvement

5.4. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab

5.5. Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

7. United States Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the United States

7.3. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in the United States

7.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

8. EU5 Epidemiology

8.1. Assumptions and Rationale

8.2. Germany Epidemiology

8.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in Germany

8.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.3. France Epidemiology

8.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France

8.3.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France

8.3.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.4. Italy Epidemiology

8.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.5. Spain Epidemiology

8.5.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.6. United Kingdom Epidemiology

8.6.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

8.6.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

8.6.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

9. Japan Epidemiology

9.1.1. Assumptions and Rationale

9.1.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

10. MEA Region Epidemiology

10.1. Assumptions and Rationale

10.2.Saudi Arabia Epidemiology

10.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.3.Egypt Epidemiology

10.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.4.UAE Epidemiology

10.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

11. China Epidemiology

11.1. Assumptions and Rationale

11.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China

11.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China

11.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

12. Russia Epidemiology

12.1. Assumptions and Rationale

12.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia

12.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia

12.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

13. KOL Views

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/deccansamachar.org/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7